Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus

Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study

(2016) D. J. Wallace et al.   ARTHRITIS CARE & RESEARCH

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

(2015) J T Merrill et al.   ANNALS OF THE RHEUMATIC DISEASES

New therapeutic avenues in SLE

(2015) Jyoti Bakshi et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Safety and Efficacy of Rituximab in Childhood-onset Systemic Lupus Erythematosus and Other Rheumatic Diseases

(2015) A. Tambralli et al.   JOURNAL OF RHEUMATOLOGY

Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials

(2015) William Stohl et al.   ARTHRITIS RESEARCH & THERAPY

The efficacy of novel B cell biologics as the future of SLE treatment: A review

(2014) Ameer Kamal et al.   AUTOIMMUNITY REVIEWS

Current role of rituximab in systemic lupus erythematosus

(2014) Chi Chiu Mok   International Journal of Rheumatic Diseases

Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody

(2014) Shui-on Leung et al.   mAbs

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

(2013) Daniel J Wallace et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study

(2013) Eduardo F. Mysler et al.   ARTHRITIS AND RHEUMATISM

Efficacy of Abatacept for Arthritis in Patients with an Overlap Syndrome between Rheumatoid Arthritis and Systemic Lupus Erythematosus

(2013) Kei Ikeda et al.   Clinical & Developmental Immunology

Systemic lupus erythematosus: an update on current pharmacotherapy and future directions

(2013) Zahi Touma et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up

(2013) Daniel J. Wallace et al.   RHEUMATOLOGY

Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006

(2013) V. Strand et al.   RHEUMATOLOGY

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

(2012) Brad H. Rovin et al.   ARTHRITIS AND RHEUMATISM

Abatacept in the treatment of lupus

(2012) Alberta Y. Hoi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

CD22 and Autoimmune Disease

(2012) Thomas Dörner et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphoma

(2012) Su Li et al.   mAbs

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon   monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study

(2011) J. T. Merrill et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Belimumab

(2011) Celeste B. Burness et al.   DRUGS

Targeting B cells with biologics in systemic lupus erythematosus

(2010) Antonio La Cava   EXPERT OPINION ON BIOLOGICAL THERAPY

The immunological basis of B-cell therapy in systemic lupus erythematosus

(2010) Mo Yin MOK   International Journal of Rheumatic Diseases

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

(2009) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus

(2009) I. Nestorov et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

(2008) Richard Furie et al.   ARTHRITIS RESEARCH & THERAPY